Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. J of Skin 2024, 8 (4), s406. https://doi.org/10.25251/skin.8.supp.406.